Laryngeal Neuroendocrine Carcinomas: A Retrospective Study of 14 Cases
Table 1
Clinical features of 14 cases with LNEC.
Case number
Age (years)
Sex
Tumor site of larynx
Tumor type
Initial treatment
Disease-free period (months)
Follow-up (months)/vital status
1
61
F
Supraglottic
TC
Endolaryngeal microsurgery
47
47/NED
2
60
F
Supraglottic
TC
TL and ND
24
24/NED
3
75
M
Glottic
AC
PL and ND
19
19/DOC
4
62
M
Supraglottic
AC
PL and ND
144
144/NED
5
66
F
Supraglottic
AC
PL, ND, and radiotherapy
48
48/DOC
6
30
F
Supraglottic
AC
PL
72
72/lost to follow-up
7
66
M
Glottic
AC
TL, ND, and radiotherapy
9
9/NED
8
53
F
Supraglottic
SCNEC
Chemotherapy and radiotherapy
72
72/NED
9
66
M
Supraglottic
SCNEC
Induction chemotherapy, radiotherapy, and adjuvant chemotherapy
20
36/DOD
10
27
F
Subglottic
SCNEC
CRT and chemotherapy
129
129/NED
11
50
M
Supraglottic
SCNEC
Chemotherapy and radiotherapy
49
49/lost to follow-up
12
54
M
Supraglottic
SCNEC
Induction chemotherapy, radiotherapy, and adjuvant chemotherapy
16
24/DOD
13
52
M
Supraglottic
SCNEC and adenocarcinoma
PL, ND, chemotherapy, and radiotherapy
30
30/lost to follow-up
14
16
F
Glottic
SCNEC
Chemotherapy and radiotherapy
5
5/DOD
TC: typical carcinoid; AC: atypical carcinoid; SCNEC: small cell neuroendocrine carcinoma; TL: total laryngectomy; PL: partial laryngectomy; ND: neck dissection; CRT: concurrent radiochemotherapy; NED: no evidence of disease; DOC: dead of other causes; and DOD: dead of disease.
